Clinical trial · Observational
Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research
Patients' Preferences in the Treatment of Hormone-sensitive Metastatic Prostate Cancer: a Discrete Choice Experiment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Systemic therapy (i.e Androgen Deprivation Therapy with Docetaxel, Enzalutamide, Apalutamide or Abiraterone Acetate) has increased overall survival in men with hormone-sensitive metastatic prostate cancer. Novel local cytoreductive treatments and metastasis directed therapy are being evaluated, these can confer additional harm, but might improve survival. We aim to elicit men's preferences for and willingness to accept trade-offs between potential improved survival and cytoreductive treatment risks using a 'discrete choice experiment'.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Health Care Utilization | — | UNRESOLVED | — |
| Patient Satisfaction | — | UNRESOLVED | — |
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
| Radiotherapy Side Effect | — | UNRESOLVED | — |
| Surgery | — | UNRESOLVED | — |
| Urologic Cancer | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Discrete Choice Experiment (DCE) Patients | Other | — | UNRESOLVED |
| Semi-Structured Interview Healthcare Professional | Other | — | UNRESOLVED |
| Semi-Structured Interview Patients | Other | — | UNRESOLVED |
| Think Aloud Interview Patients | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Healthcare Professionals (n = 5)
- description
- Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
- interventionNames
- Other: Semi-Structured Interview Healthcare Professional
- label
- Stage 1 (n = 5)
- description
- Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
- interventionNames
- Other: Semi-Structured Interview Patients
- label
- Stage 2 (n = 10)
- description
- Intervention: Single, "Think Aloud Interview" Interview. These will be analysed using an inductive thematic analysis by at least two researchers. Common themes will be extracted by researchers individually and then discussed and agreed.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosed with prostate cancer within 4 months of screening visit 2. Performance status 0-2 Exclusion Criteria: 1. Castrate-resistant metastatic prostate cancer 2. Patient has consented to a form of local cytoreductive treatment to prostate 3. Patient has consented to a form of metastasis directed therapy
References
Publications (1)
- DERIVEDConnor MJ, Genie MG, Gonzalez M, Sarwar N, Thippu Jayaprakash K, Horan G, Hosking-Jervis F, Klimowska-Nassar N, Sukumar J, Pokrovska T, Basak D, Robinson A, Beresford M, Rai B, Mangar S, Khoo V, Dudderidge T, Falconer A, Winkler M, Watson V, Ahmed HU. Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study. BMJ Open. 2021 Nov 18;11(11):e048996. doi: 10.1136/bmjopen-2021-048996. PMID 34794989